RASD1 and thyroid gland carcinoma: We observed significantly lower promoter methylation levels of RASD1 in colon adenocarcinoma (COAD), esophageal carcinoma (ESCA), head and neck squamous cell carcinoma (HNSC), KIRC, LIHC, prostate adenocarcinoma (PRAD), READ, thyroid carcinoma (THCA), and UCEC compared to normal tissues (Figure 4a–i).